key: cord-0828652-52msr1ij authors: Balaji, A.P.B.; Bhuvaneswari, Srinivasan; Nanda Kumar, D. title: Deceiving SARS-CoV-2 molecular-tropism clues – A combinational contemporary strategy date: 2020-06-07 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.109976 sha: 7d1c303ff244bbbb2204e534be50b5fbb2f0a077 doc_id: 828652 cord_uid: 52msr1ij Several attempts to control the dreadfulness of SARS-CoV-2 are still underway. Based on the literature evidences we have speculated a prospective contemporary remedy, which was categorized into Specificity, Remedy, and a Conveyor. In which, pros and cons were discussed and inferred the possible alternatives. (a) Specificity: Implicit to express the ACE2 receptors in conveyor cells to deceive SARS-CoV-2 from prepone targets. (b) Remedy: As depletion of pulmonary surfactants causes strong acute respiratory distress syndrome, we propose an entity of a cost-effective artificial surfactant system as a remedy to pulmonary complications. (c) Conveyor: We propose red blood cells (RBCs) as a conveyor with embedded artificial surfactant and protruding ACE2 receptors for the target-specific delivery. Overall we postulate focused insights by employing a combinational contemporary strategy to steer towards a prospective direction on combating SARS-CoV-2. 2 27 Abstract 28 Several attempts to control the dreadfulness of SARS-CoV-2 are still underway. Based on the 29 literature evidences we have speculated a prospective contemporary remedy, which was 30 categorized into Specificity, Remedy, and a Conveyor. In which, pros and cons were 31 discussed and inferred the possible alternatives. (a) Specificity: Implicit to express the ACE2 32 receptors in conveyor cells to deceive SARS-CoV-2 from prepone targets. (b) Remedy: As 33 depletion of pulmonary surfactants causes strong acute respiratory distress syndrome, we 34 propose an entity of a cost-effective artificial surfactant system as a remedy to pulmonary 35 complications. (c) Conveyor: We propose red blood cells (RBCs) as a conveyor with 36 embedded artificial surfactant and protruding ACE2 receptors for the target-specific delivery. 37 Overall we postulate focused insights by employing a combinational contemporary strategy 38 to steer towards a prospective direction on combating SARS-CoV-2. 152 We declare no conflict of interest 6 153 Severe acute respiratory 155 syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): 156 the epidemic and the challenges Characteristics of and important lessons from the 159 coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 160 314 cases from the Chinese Center for Disease Control and Prevention Coronaviruses: an overview of their replication and 162 pathogenesis Structural and functional basis of SARS-CoV-2 164 entry by using human ACE2 Functional assessment of cell entry and receptor 166 usage for SARS-CoV-2 and other lineage B betacoronaviruses Angiotensin-converting 169 enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential 170 therapeutic target High expression of ACE2 receptor of 2019-nCoV on 172 the epithelial cells of oral mucosa Clinical pathology of critical patient with novel 175 coronavirus pneumonia (COVID-19) Fatal case of TAFRO syndrome 177 associated with over-immunosuppression: a case report and review of the literature Pulmonary surfactant: functions and molecular composition BBA)-Molecular Basis of Disease 1408 Role of pulmonary surfactant components in 182 surface film formation and dynamics Size 185 influences the effect of hydrophobic nanoparticles on lung surfactant model systems LPS-induced lung injury in mice Development of low cost pulmonary surfactants composed of a mixture of lipids or 191 lipids-peptides using higher aliphatic alcohol or soy lecithin Improvement 194 of pulmonary surfactant activity by introducing D-amino acids into highly 195 hydrophobic amphiphilic α-peptide Hel 13-5 Drug, enzyme and 198 peptide delivery using erythrocytes as carriers Cell-penetrating peptides meditated encapsulation of 201 protein therapeutics into intact red blood cells and its application Red Blood Cell Membrane 204 Processing for Biomedical Applications The erythrocyte viral trap: transgenic 206 expression of viral receptor on erythrocytes attenuates coxsackievirus B infection Figure 1: Schematic representation of fabricating artificial surfactant loaded RBCs 212 with protruding ACE2 receptors for SARS-Co-V-2 specific binding